Mirum Pharmaceuticals, Inc.
corporate_fare Company Profile
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for MIRM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for MIRM spans 8-K, 10-Q.
Recent high-impact activity:
- Mirum's Brelovitug Hits AZURE-4 Primary Endpoint, Completing Phase 3 Package for BLA
- Brelovitug Hits Primary Endpoint in Second Phase 3, Completing Registrational Package
- Mirum 10-Q: Q3 Sales $185.7M, $898.1M Nine-Month Loss on Bluejay IPR&D Charge
- Mirum Q3 Sales $185.7M, Lifts 2026 Product Sales Guidance to $715-720M
- Mirum Lifts 2026 Sales Guidance to $715-720M After Q3 Revenue Jump to $185.7M
Financial Snapshot
Short Interest & Short Volume
11.84 days to coverFINRA reported short interest of 6,523,716 shares in MIRM as of the October 30, 2026 settlement, a 2.1% decrease from the prior period — about 11.8 days to cover at its recent average daily volume. On November 20, 2026, 64.9% of MIRM volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.